Theravance Biopharma, Inc. - Ordinary Shares (TBPH) Social Stream



Theravance Biopharma, Inc. - Ordinary Shares (TBPH): $9.05

0.00 (0.00%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add TBPH to Watchlist
Sign Up

Industry: Biotech


Ranked

of 392

in industry

Theravance Biopharma Inc (TBPH) Price Targets From Analysts

The tables below show the price targets and recommendations analysts covering TBPH.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
2021-11-09 7 $20 $8 $12.444 $9.76 27.5%
2022-02-11 6 $20 $8 $12.625 $9.76 29.35%
2022-02-25 6 $18 $9 $12.142 $9.76 24.41%
2022-03-02 6 $18 $9 $12.428 $9.76 27.34%

The Trend in the Analyst Price Target


TBPH's average price target has moved down $18.79 over the prior 14 months.

TBPH reports an average of 69.82% for its upside potential over the past 48 weeks.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Share Price Upside Potential
2021-05-15 3 42 20 30.380 18.72 62.29%
2021-07-10 3 42 20 30.000 13.71 118.82%
2021-07-24 3 42 20 29.880 13.57 120.19%
2021-08-05 3 42 20 30.000 13.45 123.05%
2022-03-02 6 18 9 12.428 10.25 21.25%

TBPH Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs
2.88 1 1 2 1 1 6

The Trend in the Broker Recommendations


Over the past 30 weeks, TBPH's average broker recommendation rating worsened by 0.78.

The points below can provide you with additional insight regarding what the price target and recommendations metrics in the table above mean for investors.

  • To contextualize these metrics, consider that out of all US stocks, Theravance Biopharma Inc's variance in analysts' estimates is lower than -517.27% of them.
  • To contextualize these metrics, consider that out of all US stocks, Theravance Biopharma Inc's average analyst price target is greater than 84.98% of them.
  • To contextualize these metrics, consider that out of Pharmaceutical Products stocks, Theravance Biopharma Inc's upside potential (average analyst target price relative to current price) is greater than 83.04% of them.
  • To contextualize these metrics, consider that out of stocks in the mid market cap category, Theravance Biopharma Inc's number of analysts covering the stock is higher than 297.75% of them.

Stocks similar to Theravance Biopharma Inc in the Pharmaceutical Products industry regarding analyst recommendations and price targets are TARO, SUPN, and STTK.

What is the outlook for TBPH? Use POWR Ratings for clearer insight into price direction.


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.6896 seconds.